Dupilumab for cancer-associated refractory pruritus

Dupilumab for cancer-associated refractory pruritus

Background: Pruritus can be an intolerable symptom in patients with cancer. Type 2 inflammation, and specifically, the cytokines IL-4, IL-13, and IL-31, play major roles in the itching process. Dupilumab is an antibody against IL-4Rα, which is a common IL-4 and IL-13 receptor subunit. Blocking IL-4...

Olles dieđut

Bibliográfalaš dieđut
Váldodahkkit: Aviv Talmon, MD, Shlomo Elias, MD, PhD, Limor Rubin, MD, Yaarit Ribak, MD, Eyal Ben Dori, MD, Oded Shamriz, MD, Michal Lotem, MD, Irit Adini, PhD, Yuval Tal, MD, PhD
Materiálatiipa: Artihkal
Giella:English
Almmustuhtton: Elsevier 2023-08-01
Ráidu:Journal of Allergy and Clinical Immunology: Global
Fáttát:
Oncologic pruritus
chronic pruritus
itch
IL-4
IL-13
IL-31
Liŋkkat:http://www.sciencedirect.com/science/article/pii/S277282932300053X

Interneahtta

http://www.sciencedirect.com/science/article/pii/S277282932300053X

Geahča maid